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Sirolimus, a macrocylic lactone, blocks T-cell activation by a
mechanism of action distinct from calcineurin inhibitors
(CNIs). Therefore, it may be expected that sirolimus would
display a safety profile without the vasomotor form of
nephrotoxicity characteristic of CNIs. Initial studies in rodent
models and in psoriasis patients showed that sirolimus alone
did not impair renal function. Subsequently, two pivotal,
randomized double dummy, phase III trials in human renal
transplantation demonstrated that sirolimus exacerbated the
nephrotoxicity of full doses of CNIs. Both pharmacokinetic
and pharmacodynamic mechanisms have been implicated in
the pathogenesis of this disorder. Subsequent experience has
shown that cyclosporin A dose reduction, elimination, or
avoidance mitigates these effects, particularly in patients
distant from the transplant procedure. However, there is
concern about recovery from ischemia–reperfusion injury.
Animal models suggesting that sirolimus may delay recovery
in this setting have been supported by non-randomized
experiences at single centers, which have observed an
increased incidence of delayed graft function among
sirolimus-treated recipients. In contrast, large single- and
multi-center studies have not confirmed this finding;
impaired renal recovery has been observed in only occasional
instances. Thus, present data indicate that sirolimus does not
impair the function of an uninjured kidney, but whether the
drug acts alone or potentiates conditions that delay recovery
after ischemic injury remains to be established by large
randomized trials specifically targeted to recipients at high
risk for this complication.
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Sirolimus is a natural macrocyclic lactone fermentation
product of Streptomyces hygroscopicus. Its mechanism of
action is distinct from cyclosporine A (CsA) and tacrolimus
that inhibit cell activation. In contrast, sirolimus prevents the
proliferation and clonal expansion of cells stimulated by
cytokines or growth factors via blockade of mammalian
target of rapamycin, a kinase that is widely distributed among
tissues. Mammalian target of rapamycin phosphorylates a
variety of cell cycle intermediates and catalyzes processes
necessary for gene transcription and protein translation. The
blockade disrupts progression through the G1 phase of
activation.1 Because it acts on a target independent of
calcineurin, sirolimus might be predicted to display a safety
profile free of the vasomotor nephrotoxicity produced by
calcineurin inhibitors (CNIs), engendering an important
addition to the immunosuppressive armamentarium. Addi-
tionally, preclinical in vitro and in vivo studies have
demonstrated that combination treatments with sirolimus
and CsA produce synergistic immunosuppression, because
the two drugs act at sequential steps of immune activation.2
RENAL EFFECTS OF SIROLMUS ON NATIVE KIDNEYS
Sirolimus in animal models
Initial work examining the effects of sirolimus (1 mg/kg/day
for 14 days) failed to observe any functional or histological
effects of the drug on rat kidneys. Only at grossly supra-
therapeutic doses of 10 mg/kg/day did sirolimus produce a
nonsignificant decrease in creatinine clearance. In compar-
ison, CsA depressed creatinine clearance by 44% and induced
proximal tubular damage.3 However, animals treated for 14
days with sirolimus (1.5 mg/kg/day by intraperitoneal injec-
tion), or CsA (15 mg/kg/day by gavage), or both drugs in
combination, showed that the glomerular filtration rate
(GFR) was not significantly affected by treatment with
sirolimus alone, but was reduced by 28% with CsA alone, and
61% using the drug combination.4 Another study in rats
treated for 7 days revealed significantly upregulated expres-
sion of kidney injury molecule-1 with the drug combination
compared with sirolimus (0.8 mg/kg/day) alone or CsA
(5 mg/kg/day) alone.5 In a further study of 60 days treatment
with lower, albeit still supra-therapeutic doses, of sirolimus
(2.0 or 0.5 mg/kg orally), rabbits exhibited no differences
with respect to blood pressure, GFR, renal blood flow,
or serum creatinine (Scr). Nonetheless, morphological
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assessment of the kidneys manifested tubular atrophy and
interstitial fibrosis, as well as arteriopathy.6
Because both drugs are metabolized by the same isoforms
of cytochrome P450 and react with p-glycoprotein, one
would predict pharmacokinetic interactions between CsA
and sirolimus. Podder et al.7 treated groups of rats for 14 days
with CsA alone (2.5–20.0 mg/kg), sirolimus alone
(0.4–6.4 mg/kg), or combinations of CsA (2.5–20.0 mg/kg)
plus sirolimus (0.4–6.4 mg/kg). The higher Scr concentrations
observed with the combination compared with either
monotherapy group correlated with proportionate elevations
of whole blood and particularly renal and liver tissue trough
concentrations of CsA. Histologic studies showed that the
addition of sirolimus to a CsA regimen accelerated the
appearance of histopathologic findings.7 As the therapeutic
doses in man have never exceeded 0.2 mg/kg/day, none of
these studies are particularly relevant to the clinical situation,
although the drug–drug interaction has been demonstrated
even at low exposures.8 Thus, exacerbation of renal dysfunc-
tion seems to be due, in great part, to a pharmacokinetic inter-
action of sirolimus to particularly increase CsA concentrations
in kidney tissue.
Sirolimus in patients affected by psoriasis
A European multi-center trial examined the effects on the
native renal function, among 150 patients, of sirolimus
(0.5 mg, 1.5 mg, or 3.0 mg/m2 daily for 8 weeks) alone or in
combination with a subtherapeutic dose of CsA (1.25 mg/kg/
day) for the treatment of severe chronic plaque psoriasis. CsA
(5 mg/kg/day) was the positive control and CsA (1.25 mg/kg/
day) alone the negative control.9 This trial was based on a
previous study that demonstrated that 5 mg/kg/day doses of
CsA were associated with progression to nephropathy in 40%
of patients with autoimmune diseases, all of whom had
normal renal function before inception of treatment.10 The
Scr levels of patients receiving sirolimus monotherapy (up to
3.0 mg/m2) were preserved, whereas those prescribed a
combination regimen with a subtherapeutic dose of CsA
experienced impairments, although not as severe as for
subjects treated with 5 mg/kg/day CsA alone.
DE NOVO SIROLIMUS THERAPY WITH CNIS IN RENAL
TRANSPLANTATION
Phase I, II, and III studies
The phase I study of addition for 14 days of 0.5, 1, 3, or 5 mg/
m2 sirolimus to the CsA regimen of stable patients more than
6 months post-transplantation failed to show an adverse
nephrotoxic interaction.11 Furthermore, the phase IIA study
of de novo treatment of recipients of renal allografts from
living-related donors demonstrated the efficacy of this
regimen for the prophylaxis of acute rejection and failed to
show a significant adverse effect on renal function.12 The
phase IIB study suggested that non-African-American
recipients treated with halved exposures to CsA yielded good
rejection prophylaxis and displayed better renal function than
the full exposure cohort.13
Based on that work, two phase III multi-center, rando-
mized, double-blind, double-dummy, pivotal trials were
conducted in human renal transplantation. As the studies
were blinded, they compared outcomes of patients receiving
fixed doses of sirolimus (2 or 5 mg/day) versus either
placebo (Global Study14) or azathioprine (United States
Study15) in combination with full exposures to CsA and
corticosteroids.
In the Global Study of 576 patients, subjects randomized
to receive sirolimus showed significantly lower incidences of
biopsy-confirmed acute rejection than the placebo arm.
However, at both 3 and 6 months, the 5 mg/day sirolimus
group displayed a lower mean GFR value (calculated by the
Nankivell method) than the placebo group. In the US trial of
719 patients, those recipients randomized to sirolimus
prescription experienced a significantly lower frequency of
acute rejection episodes, but significantly reduced mean
creatinine clearance values at both 6 and 12 months
compared with the azathioprine group.
These pivotal trials raised concern that the drug either had
a subclinical adverse effect on renal function or exacerbated
the nephrotoxicity of CNIs. Importantly, both pivotal studies
showed prominent pharmacokinetic interactions: lower CsA
doses were necessary to achieve target blood trough
concentrations among sirolimus versus comparator groups.
These results were confirmed by an examination of registry
data comparing the outcomes of patients who underwent
renal transplantation in the early period after Food and Drug
Administration approval between 1998 and 2003. Recipients
initially treated with CsA plus sirolimus (n¼ 1999) experi-
enced significantly poorer graft survival (75 versus 79% at 4
years, P¼ 0.002) and lower mean estimated creatinine
clearances than those treated with CsA plus mycophenolate
mofetil (MMF; n¼ 21 017).16 These observations indicated
that downward adjustment in doses (minimization), cessa-
tion (withdrawal), or avoidance of CNI would be necessary to
mitigate the renal toxicity. Unfortunately, no large data set
was available to address these questions and assist clinicians
in their choice of initial CNI exposure.
Sirolimus and tacrolimus
A multi-center, unblinded, randomized, clinical trial com-
pared the outcomes of tacrolimus plus steroid-based
immunosuppression with sirolimus (n¼ 185) versus with
MMF (n¼ 176). Tacrolimus doses were adjusted to maintain
levels in the range of 8–16 ng/ml for 3 months post-
transplant, followed by 5–15 ng/ml thereafter. Sirolimus
dosing was adjusted to achieve levels of 4–12 ng/ml. At 1
year, there was no difference in patient or graft survival. Yet,
patients receiving MMF displayed significantly better renal
function, as shown by their lower median Scr levels (1.3
versus 1.5 mg/dl, P¼ 0.03) and the greater rate of patients in
the sirolimus group having an Scr 42.0 mg/dl (20.4 versus
11.0%, P¼ 0.02). Median calculated creatinine clearances
(Cockcroft–Gault), however, were not significantly different
(58.4 versus 54.3 ml/min). This study, using exposure to full
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doses of tacrolimus, produced results remarkably similar to
the earlier trials using full doses of CsA.17
Sirolimus and CsA minimization
To determine whether minimization would improve renal
function, a multi-center study randomized 631 sirolimus/
steroid-treated renal allograft recipients to either reduced
doses (100–225 for months 1–2, tapered to 50–100 ng/ml by
month 7 post-transplantation, n¼ 332) or full doses of CsA
(250–400 for months 1–2, tapered to 150–300 ng/ml by month
7, n¼ 321). Although the graft survivals (98 versus 98%) and
acute rejection rates (13 versus 15%) were equivalent between
groups, the mean Scr at 12 months in the reduced group
(1.6871.0) was impaired but significantly better than that of
the full-dose group (1.970.8, P¼ 0.001). It was evident that
sirolimus in combination with reduced doses of CsA and
steroids might improve quality of renal function compared to
therapy with full-dose CsA and sirolimus (Cohen J,
Muehlbacher F, for the US and European Sirolimus CsA
Study Groups. A regimen of sirolimus and reduced-dose
cyclosporine results in improved renal allograft function:
combined analysis of the US and European sirolimus–cyclos-
porine trials. Am J Transplant 2004; 4: 284 (abstract)).
Even greater benefits were observed in a retrospective
review of 427 renal transplant recipients from our own
center. The patients were treated with sirolimus (C0 10–15 ng/
ml) and abbreviated courses of corticosteroids. The cohorts
were stratified into three groups based on CsA doses: 45
(50% reduction), 2.4–5 (66% reduction), or o2.4 mg/kg
(85% reduction). Although there was no significant differ-
ence between groups in the incidence of acute rejection, there
was a clear benefit of reduced CsA exposure on mean creati-
nine clearance calculated at 2 years (59.4724, 68.1723
versus 73.0727 ml/min, respectively; P¼ 0.0001, data submitted
for publication).
Reduction in tacrolimus exposure by 50% (C0 3–7 ng/ml)
in combination with sirolimus only produced a trend
(P¼ 0.09) toward better renal function in an initial
Australian study, which was subsequently shown to be
significant in a multi-national, open-label, multi-center trial,
namely a mean creatinine clearance of 7071.52 (reduced-
exposure group) versus 58.971.59 ml/min7s.e.m. (full-
exposure group, Po0.001; Russ et al.18 and (Whelchel J,
Paczek L, Bechstein W et al. A regimen of sirolimus and
reduced-dose tacrolimus results in improved renal allograft
function: combined analysis of the North American TARGET,
European and Australian sirolimus–tacrolimus trials. Am J
Transplant 2003; 3:464 (abstract)).
Sirolimus and CsA elimination
An alternative approach that was explored in a European
study completely eliminated the use of CsA after 3 months
post-transplantation. This design was based on the premise
that the synergistic immunosuppressive effect would mini-
mize the occurrence of rejection during the critical initial
3-month period and that the adverse effects on renal function
would be reversible upon discontinuation. In this trial, 525
almost exclusively Caucasian, renal transplant patients
initially received sirolimus (trough level 45 ng/ml), CsA
(150–400 ng/ml), and steroids. At 3 months, eligible patients
who had not undergone a Banff grade 3 or vascular rejection
episode were randomly assigned to remain on sirolimus–
CsA–prednisone therapy (n¼ 215) or to have CsA withdrawn
(n¼ 215) while increasing sirolimus exposure in combina-
tion with steroids. At 48 months, the CsA-eliminated,
sirolimus–steroid-treated cohort showed significantly better
graft survival (91.5 versus 84.2%, P¼ 0.024). Additionally,
the mean values for calculated Nankivell GFR were
significantly better among the sirolimus–steroid-treated
patients from 6 to 48 months. Additionally, at most time
points from 6 to 48 months, the sirolimus–steroid-treated
group displayed significantly better mean arterial blood
pressure compared with patients receiving sirolimus–CsA–
steroids. At 48 months after randomization, there appeared
to be insignificant differences between double and triple
therapy groups in the incidences of biopsy-proven acute
rejection (10.2 versus 6.5%) and mortality (7.9 versus 4.7%),
although the cohorts were really not large enough to robustly
assess the risk of CsA elimination.19 A preliminary report of a
Spanish trial suggested that the risk of CNI elimination may
be mitigated among patients receiving tacrolimus.20
Protocol renal biopsies that were performed in a minority
of subjects, namely 25.6% of on-therapy patients, or 14.6% of
all randomized patients, sought to use the Chronic Allograft
Damage Index to predict progression to chronic rejection
and graft loss, from engraftment to 12 and 36 months after
transplantation. Although no treatment effect was evident
with paired baseline and 12-month biopsies, at 36 months
the Chronic Allograft Damage Index score was significantly
lower among the sirolimus–steroid (n¼ 37) versus the
sirolimus–CsA–steroid cohort (n¼ 40: 3.20 versus 4.70,
P¼ 0.003).21 This study has been criticized owing to the
likelihood of induction of a serious CsA nephrotoxic lesion
owing to the high drug exposures de novo. A study
investigating the benefit with reduced de novo CsA exposures
would be more informative. However, its relevance to
transplant practice in the United States has been questioned,
as the recipients were of low immunologic risk. In addition,
the study was not adequately powered to evaluate the
significance of the risks after CsA discontinuation.
Late conversion from CNI to sirolimus
The potential benefit of conversion from CNI-based to
sirolimus-based immunosuppression for the management of
impaired renal transplant function has been explored in a
number of recent studies. In a large prospective, open-label
trial of 830 renal transplant patients receiving CNIs for 6–120
months, patients were randomly assigned (1:2) over 2 years
to either continue the CNI (n¼ 275) or undergo conversion
from CNI to sirolimus (n¼ 555). Among patients with base
line GFR440 ml/min that remained on therapy after 12 months,
the mean change from baseline GFR was þ 1.4 ml/min for
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the sirolimus group and 1.3 ml/min for the CNI group
(P¼ 0.003). Rates of acute rejection, graft, and patient
survival were comparable between the groups (Schena FP,
Wali RK, Pascoe MD et al. Efficacy and safety of conversion
from calcineurin inhibitors to sirolimus versus continued
use of calcineurin inhibitors in renal allograft recipients:
12-month results from a large, randomized, open-label,
comparative trial. J Am Soc Nephrol 2005; 16:33A (abstract)).
Similarly, a single-center study was designed to determine
whether conversion form CNIs to sirolimus would retard
progression of chronic allograft nephropathy (CAN). A total
of 84 patients with biopsy-proven CAN were randomized to
receive either a 40% CNI reduction plus MMF (n¼ 51) or
conversion to sirolimus (C0 6–10 ng/ml). At the end of the
24-month follow-up period, 25 patients underwent a second
renal biopsy: 10 in the CNI reduction group and 15 in the
sirolimus conversion group. Although renal function and
Banff grading were similar at randomization, graft survival
was significantly better among the sirolimus group
(P¼ 0.037). The CAN grade worsened significantly among
the CNI-MMF reduction group, whereas it remained stable
in the sirolimus group. The expression of interstitial and
vascular a-smooth muscle actin protein, a marker of
fibroblast activation, was significantly increased in biopsies
from the CNI-reduction-MMF group (P¼ 0.005), whereas it
was reduced in the sirolimus-treated group (P¼ 0.005).
However, the study did not report a significant improvement
in graft function in sirolimus-treated versus CNI-MMF-
treated patients.22
Sirolimus and CsA avoidance
As the combination of sirolimus and full-dose CNI caused
impaired renal allograft function and the optimal CNI
exposure during combination therapy is presently uncertain,
a third option is complete avoidance of a CNI. Two phase II
randomized multi-center European trials, including a total of
161 subjects, directly compared the effects of sirolimus versus
CsA on renal function in de novo human renal transplant
recipients. Both studies had a randomized, open-label,
parallel-group design, comparing combinations with cortico
steroids plus azathioprine (study A) or corticosteroids plus
MMF (study B). In both trials, CsA dosages were adjusted to
maintain whole-blood trough levels of 200–400 ng/ml for
2 months, and 100–200 ng/ml thereafter. Sirolimus doses
were adjusted to achieve steady-state whole-blood trough
levels of approximately 30 ng/ml for 2 months, and 15 ng/ml
thereafter.
As early as 8 weeks post-transplantation, mean Scr levels
were consistently lower in the sirolimus compared to the CsA
group with significant differences at 11, 12, 16, 20, and 32
weeks, as well as 1 and 2 years of treatment, whereas the
incidences of acute rejection episodes, graft loss, or death
were similar between the groups. The calculated GFR
(Nankivell method) was significantly higher among the
sirolimus group from weeks 9 to 32 and after year 1 of
treatment. The incidence and mean serum levels of uric acid
and potassium were significantly higher and the average
serum magnesium concentration significantly lower in the
CsA group. Patients treated with sirolimus had a lower
incidence of hypertension than CsA-treated recipients.
Sirolimus-treated patients displayed greater urine output
and lower serum potassium levels, suggesting some tubular
injury. However, the relevance of these studies to general
transplant practice is not great, as recipients in these trials
tended to be of low immunologic risk.23
A single-center, randomized, prospective trial in 61 renal
transplant recipients compared concentration-controlled
sirolimus (C0 10–12 ng/ml) with trough level CsA-based
immunosuppression (C0 4200 ng/ml) in combination with
basiliximab, MMF, and steroids. At 2 years post-transplant,
55 patients underwent renal function studies, 48 had
transplant biopsies, all classified by the Banff 1997 scoring
system and 41 analysis by DNA microarrays. Comparing
sirolimus with CsA revealed significantly higher GFR by
iothalamate clearance (60.6 versus 49.2 ml/min, P¼ 0.018)
and greater incidence of Banff grade 0 biopsies (66.6 versus
20.8%, P¼ 0.013). Regression analysis of calculated GFRs
from 1 to 36 months yielded a positive slope for sirolimus of
3.36 ml/min/year versus a negative slope for CsA, namely
1.58 ml/min/year (P¼ 0.008). Gene expression profiles
from kidneys with higher Banff scores for CAN suggested
significant upregulation of genes related to immune/inflam-
mation and fibrosis/tissue remodeling.24 These data have led
to the hope for better renal function and presumably longer
survival of allografts with CNI avoidance.
A recent randomized, open-label study, primarily in
Caucasian recipients of living donor kidneys has challenged
this hope. In addition to thymoglobulin induction and
maintenance treatment with MMF (750 mg p.o. b.i.d.) and
steroids, 81 patients received sirolimus (C0 15–20, 5–10 ng/ml
beyond 6 months) versus 84 who were prescribed tacrolimus
(C0 10–12 ng/ml). The drop-out rates were 38 and 16%,
respectively. An intent-to-treat analysis showed similar rates
of patient and graft survivals, as well as acute rejection
episodes. Whereas the sirolimus cohort showed significantly
higher iothalamate clearances than the tacrolimus arm at
1 month, at 1 and 2 years, there was no difference. At
24 months, the values were 57717 versus 56714 ml/min,
respectively. However, the tacrolimus groups showed a
greater incidence of chronic vascular changes than the
sirolimus cohort: 43 versus 26% (P¼ 0.03).25 Although this
difference may forecast improved long-term outcomes for the
sirolimus arm, the greater incidence of dyslipidemia and
anemia among patients treated with high exposures to this
drug may mitigate this advantage. This important study
needs to be performed in recipients of deceased donor
transplants, particularly high-risk African-American or
sensitized patients to define its general applicability. Further-
more, a seminal study would assess full exposure to
tacrolimus-MMF versus a cohort of patients with reduced
tacrolimus doses (C0 2–5 ng/ml) in combination with reduced
amounts of sirolimus (C0 5–10 ng/ml).
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SIROLIMUS AND RECOVERY FROM ACUTE RENAL FAILURE
By inhibiting the proliferation of a number of non-immune
cell types, including hepatocytes, vascular endothelium,
smooth muscle cells, and fibroblasts, sirolimus may poten-
tially interfere with the recovery of tubular cells after
ischemic–reperfusion injury.
Leiberthal et al. observed that sirolimus inhibited prolif-
eration of cultured mouse proximal tubular cells and pro-
moted apoptosis. After ischemic acute renal failure induced by
native renal artery occlusion, the GFR fell to comparable levels
in both sirolimus- and vehicle-treated rats on day 0. Vehicle,
but not sirolimus-treated rats, showed significant improve-
ment by day 4. Furthermore, sirolimus increased apoptosis
and reduced proliferative responses of tubular cells, effects
that they attributed to inhibition of a 70-kDa S6 protein
kinase, a substrate of mammalian target of rapamycin.26
In a syngeneic rat kidney transplant model, Fuller et al.27
showed that after 24 h storage in University of Wisconsin
solution, the mean Scr of sirolimus-treated animals (C0
16.671.6 ng/ml on day 1) was significantly higher than that
of vehicle-treated animals at days 1–4 post-transplant. Graft
histology showed only rare necrotic tubular epithelial cells in
the vehicle-treated animals, whereas frank tubular epithelial
cell necrosis was evident in kidneys from sirolimus-treated
animals.27
A retrospective analysis of 132 consecutive cases of delayed
graft function (DGF) after deceased donor renal transplanta-
tion at the University of California San Francisco included 55
sirolimus-treated patients (C0 10–15 ng/ml) in combination
with MMF and corticosteroids. Cox proportional hazards
analysis of time to graft function suggested that sirolimus had
a highly significant effect (hazard ratio 0.48, P¼ 0.007).28
A single-center retrospective review of DGF among 144
renal allograft recipients transplanted at the University of
Washington reported a greater incidence of DGF among
patients treated with sirolimus (C0 10 ng/ml) and tacrolimus
(C0 7–10 ng/ml; n¼ 88) than those with tacrolimus and MMF
(n¼ 56; 25 versus 8.9%, P¼ 0.02). The risk of DGF seemed
to increase with increasing sirolimus doses (P¼ 0.008).
Additionally, among patients with tubular injury on biopsy,
12 patients treated with sirolimus developed intratubular cast
formation.29
However, as these patients received high exposures to CNI,
the impact of sirolimus was more likely owing to its
pharmacokinetic effects to augment the nephrotoxicity of
those agents than to an intrinsic effect. Furthermore, as the
analysis was performed post hoc, there is the possibility that
sirolimus was prescribed for patients whose grafts were at
increased risk of DGF based upon the belief that the drug is
non-nephrotoxic compared with CNIs.
In contrast, larger prospective studies of de novo treatment
with CNIs plus sirolimus have not consistently shown an
increased risk of DGF. In the phase II study, recipients
randomized to receive sirolimus versus CsA-based immuno-
suppression showed similar incidences of DGF, namely 11
versus 6%, respectively (P¼ 0.4).23 In a study comparing
full-dose tacrolimus plus sirolimus to tacrolimus plus MMF,
patients receiving MMF experienced a greater incidence of
dialysis in the first week post-transplantation (21.0 versus
11.9%, P¼ 0.02).17 Finally, only 14% of 145 recipients in a
single-center study experienced DGF, demonstrating the
benefit associated with a concentration-controlled regimen
of sirolimus (C0 10–15 ng/ml) in combination with delayed
introduction of reduced doses of CsA (C0 25–75 ng/ml).
Moreover, when patients were stratified into three groups
based on sirolimus trough concentrations at 1 week post-
transplantation, recipients with the highest exposure to
sirolimus exhibited lower mean Scr values and higher
calculated GFRs (Cockcroft–Gault) at 1 week.30 Although
there exists the possibility that the antiproliferative effects of
sirolimus on renal tubular cells impair recovery from
ischemia–reperfusion injury, it is more likely in our opinion
that the effect of sirolimus to disrupt injurious cytokine
signals outweighs this hazard.
CONCLUSIONS
In summary, therapeutic doses of sirolimus seem to preserve
GFR in animals and humans bearing two kidneys. Indeed,
conversion of stable post-renal transplant patients who
display mild to moderate graft impairment from CNI to
sirolimus tends to improve renal function and delay
progression of CAN. Whereas the nephrotoxicity of full-dose
CNIs is exacerbated by combination therapy with sirolimus,
owing to pharmacokinetic and possibly dynamic interactions,
we believe that CsA exposure may be reduced by more than
80%, thereby avoiding injury with good allograft protection
from rejection and long-term renal function (Figure 1). In
cases of severe ischemia–reperfusion injury, some animal and
retrospective patient data suggest an effect of sirolimus to
impair recovery from a tubular injury. However, randomized,
multi-center, and larger single-center studies have not
confirmed this hypothesis. A relatively small fraction of
patients treated with sirolimus de novo may show prolonga-
tion of DGF. Whether sirolimus exacerbates or protects the
transplanted kidney from an ischemic injury will need to be
dissected in large prospective trials.
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Figure 1 | Cyclosporine/sirolimus combination. Relation of drug
concentrations to hazard of biopsy-proven acute rejection episode or
of a creatinine clearance (from Lisik W, Kahan BD. Proliferation signal
inhibitors: chemical, biological and clinical properties. Transplant Rev
2006; 19: 186–122).
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